MAX and central nervous system cancer: Under “Established SCNAs in Glioma”, the most frequently reported SCNA events were CDK6 amplification (55.17% of analyses), MET amplification (50%), CDKN2A deletion (44.83%), EZH2 amplification (44.83%), BRAF amplification (43.1%), CDKN2B deletion (43.1%), EGFR amplification (39.66%), RB1 deletion (22.41%), MAX deletion (20.69%), and NF2 deletion (20.69%, Fig. 4c, left).